Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of miR-124-3p agonist to preparation of IL4R alpha protein expression inhibitor

A protein expression and agonist technology, applied in the field of medicine, can solve the problem of not being able to obtain good curative effect, and achieve the effect of inhibiting the increase of the number

Inactive Publication Date: 2021-11-30
THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still some patients who cannot obtain good curative effect with existing drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miR-124-3p agonist to preparation of IL4R alpha protein expression inhibitor
  • Application of miR-124-3p agonist to preparation of IL4R alpha protein expression inhibitor
  • Application of miR-124-3p agonist to preparation of IL4R alpha protein expression inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 Modeling of allergic rhinitis mice

[0048] Experimental animals: C57BL / 6J female mice aged 6-8 weeks were randomly divided into 3 groups, 5 mice in each group. Group C was the normal saline control group, AR was the dust mite-sensitized allergic rhinitis group, and T was miR - 124-3p agonist treatment group.

[0049] AR modeling: divided into two stages: abdominal sensitization and nasal stimulation. Intraperitoneal sensitization stage: 40 μg of HDM (Stallergenesgreer, US) was dissolved in 200 μL of normal saline, and the mice were injected intraperitoneally on the 1st, 5th, 10th, and 15th day, respectively. Nasal challenge phase: 10 days in a row from day 16 to day 25, challenge with 20 μg HDM dissolved in 20 μL of normal saline every day, 10 μL in each nasal cavity.

[0050] The difference between miR-124-3p agonist treatment group T group mice and AR modeling mice was that 1.4 nmol miR-124-3p agonist was given nasal drop intervention 3 hours before each ...

Embodiment 2

[0052] Example 2 Application of miR-124-3p agonist in alleviating nasal symptoms in mice with allergic rhinitis

[0053] For the three groups of mice prepared in Example 1, within 15 minutes after the last nasal drop, the number of sneezes of the three groups of mice was observed.

[0054] Experimental results such as figure 2 As shown, it can be seen from the figure that the miR-124-3p agonist can effectively reduce the nasal symptoms of mice with allergic rhinitis. After treatment with miR-124-3p agonist, the nasal The external symptoms can basically reach the level of normal mice.

Embodiment 3

[0055] Example 3 miR-124-3p agonists inhibit dust mite-specific IgE levels in the serum of mice with allergic rhinitis

[0056] Eyeballs of the three groups of mice prepared in Example 1 were removed to collect blood, and the serum obtained by centrifugation was used to detect dust mite-specific IgE levels using an ELISA kit (Invitrogen).

[0057] Experimental results such as image 3 As shown, it can be seen from the figure that miR-124-3p agonist can effectively reduce the expression level of dust mite-specific IgE protein. After treatment with miR-124-3p agonist, dust mite in mice with allergic rhinitis The expression level of specific IgE protein can basically reach the level of normal mice in the control group.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a miR-124-3p agonist to preparation of an IL4R alpha protein expression inhibitor. The miR-124-3p agonist provided by the scheme of the invention can significantly inhibit protein expression of IL4R alpha, and reduce protein expression quantities of IL4 and IL13 at the same time, and has important significance for treating allergic rhinitis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of miR-124-3p agonists in the preparation of IL4Rα protein expression inhibitors. Background technique [0002] Human interleukin 4 (IL4, IL-4), also known as BCGF-1, BCGF1, BSF-1, BSF1, etc., is mainly produced by activated T cells and participates in humoral immunity and adaptive immunity. Cytokines that differentiate cells into Th2 cells. The human IL-4 gene is located at 5q31.1, consisting of 4 exons and 3 introns, about 10kb. The mature human IL-4 molecule consists of 129 amino acid residues, with a molecular weight of 15kDa and two glycosylation sites. All the biological functions of IL-4 are mediated through the interleukin 4 receptor (IL-4R) on the surface of effector cells. IL4R is composed of α and γ subunits. IL-4 and IL-4R bind to IL-4Rα chain conduct signal transduction. Human IL-4Rα is located in the 16p12.1 region, and the gene and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61P11/02A61P37/08
CPCA61K45/00A61P11/02A61P37/08
Inventor 刘鸿慧刘芊侯明华沈阳王天生谭国林
Owner THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com